ReviewJournal of clinical medicine2024
New-Onset Diabetes Mellitus after Kidney Transplantation.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of belatacept versus calcineurin inhibitors on risk of post-transplant diabetes mellitus in kidney transplant recipients.Frontiers in immunology · 2026Pooled it
- GLP-1 receptor agonists in kidney transplant recipients with post-transplant diabetes: efficacy and safety outcomes from a retrospective cohort study.Archives of endocrinology and metabolism · 2026Article
- Post-transplant metabolic dysregulation: Insights and implications for kidney graft survival.World journal of nephrology · 2026Review
- Finerenone in kidney transplantation: an underinvestigated agent: review of available evidence, existing gaps, and future directions.Clinical transplantation and research · 2026Review
- Incidence and risk factors of post-transplant diabetes mellitus among kidney transplant recipients: a retrospective study from a tertiary center in Saudi Arabia.BMC nephrology · 2025Article
- Trends and predictors of diabetes mellitus after living kidney transplantation: A retrospective study.World journal of diabetes · 2025Article
- Kidney Transplant: More than Immunological Problems.Journal of clinical medicine · 2025Review
- Exploring the Impact of Diabetes on Kidney Transplant: Patient Outcomes and Management Strategies.Cureus · 2025Review
- Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment.Journal of clinical medicine · 2025Review
- New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences.Diagnostics (Basel, Switzerland) · 2025Review
- Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Elevated Plasma High Sensitive C-Reactive Protein and Triglyceride/High-Density Lipoprotein Cholesterol Ratio are Risks Factors of Diabetes Progression in Prediabetes Patients After Kidney Transplant: A 3-Year Single-Center Study in Vietnam.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New-Onset Diabetes Mellitus after Transplantation (NODAT) emerges as a prevalent complication post-kidney transplantation, with its incidence influenced by variations in NODAT definitions and follow-up periods. The condition's pathophysiology is marked by impaired insulin sensitivity and β-cell dysfunction. Significant risk factors encompass age, gender, obesity, and genetics, among others, with the use of post-transplant immunosuppressants intensifying the condition. NODAT's significant impact on patient survival and graft durability underscores the need for its prevention, early detection, and treatment. This review addresses the complexities of managing NODAT, including the challenges posed by various immunosuppressive regimens crucial for transplant success yet harmful to glucose metabolism. It discusses management strategies involving adjustments in immunosuppressive protocols, lifestyle modifications, and pharmacological interventions to minimize diabetes risk while maintaining transplant longevity. The importance of early detection and proactive, personalized intervention strategies to modify NODAT's trajectory is also emphasized, advocating for a shift towards more anticipatory post-transplant care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.